2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2023)

TRITON3: Rucaparib improves rPFS in BRCA-altered mCRPC

Elaine Soliven, 20230310000000

Treatment with rucaparib significantly improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), particularly those with BRCA alterations, compared with the physician’s choice of therapy of docetaxel or a second-generation ARPI*, according to the TRITON3 trial presented at ASCO GU 2023.

mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups

Christina Lau, 20230310000000

Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.

CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer

Audrey Abella, 20230308100000

In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.

Darolutamide-containing triplet regimen ups survival in mHSPC regardless of disease volume, risk

Audrey Abella, 20230306100000

In a post hoc analysis of the phase III ARASENS study, the triplet regimen comprising darolutamide, androgen deprivation therapy (ADT), and docetaxel continued to show overall survival (OS) benefit for metastatic hormone-sensitive prostate cancer (mHSPC) irrespective of disease volume and risk.

Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC

Christina Lau, 20230306000000

Rucaparib significantly improves radiographic progression-free survival (rPFS) vs physician’s choice of docetaxel, abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring BRCA alterations whose disease has progressed after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI), results of the phase III TRITON3 trial have shown.

Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer

Jairia Dela Cruz, 20230303140000

The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.

Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma

Stephen Padilla, 20230303120000

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Final PROpel data confirm OS advantage with abiraterone plus olaparib

Jairia Dela Cruz, 20230301150000

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

SRT plus GnRH agonist with acetate/prednisone, apalutamide improves prostate cancer survival

Stephen Padilla, 20230224120000

Postoperative salvage radiotherapy (SRT) plus 6 months of androgen deprivation therapy (ADT) with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) results in better progression-free (PFS) and metastasis-free survival (MFS) among patients with prostate cancer, findings from FORMULA-509 have shown. However, the primary analysis did not reach the prespecified threshold for statistical significance.